Active

Psoriatic Arthritis

Active

Ankylosing Spondylitis

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

For moderate to severe rheumatoid arthritis (RA) in adult MTX‑IR patients1

Older woman in a harness, ziplining
Durable remission even without MTX Durable remission even without MTX Durable remission even without MTX

RINVOQ achieved DAS28-CRP<2.6* (ranked secondary endpoint) at Week 12 or 14, with durable remission rates up to 84 weeks. Remission was also evaluated using additional measures.1,3-9

*Does not mean drug-free remission or complete absence of disease activity

CRP=C-reactive protein; DAS28=disease activity score 28 joints;
IR=intolerance or inadequate response; MTX=methotrexate

Clinical Trial Overview

SELECT-COMPARE: Primary endpoint was ACR20 response at Week 12 MTX-IR

*P≤0.001 RINVOQ vs Placebo

SELECT‑COMPARE (Study RA-IV) Study Design Intro:1,5
48‑week, randomized, double‑blind,
active comparator-controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX. The primary endpoint was ACR20 response at Week 12 vs Placebo. Prespecified blinded rescue protocol occurred at weeks 14, 18, 22, or 26.

SELECT-MONOTHERAPY: Primary endpoint was ACR20 response at Week 14 MTX-IR

*P<0.0001 RINVOQ vs MTX

SELECT‑MONOTHERAPY (Study RA-II) Study Design Intro:1,8 
14‑week, randomized, double‑blind, active comparator‑controlled study of 648 adult patients with moderate to severe RA who had an inadequate response to MTX. The primary endpoint was ACR20 response at Week 14.

Remission data across measures at week 12 or 14 Remission data across measures at week 12 or 14 Remission data across measures at week 12 or 14

SELECT‑COMPARE:
Clinical Remission Data (Week 12)

~30% of RINVOQ + MTX patients achieved Remission (DAS28‑CRP<2.6)

SELECT‑MONOTHERAPY:
Clinical Remission Data (Week 14)

~30% of RINVOQ patients achieved
Remission (DAS28‑CRP<2.6)

SELECT-MONOTHERAPY: Clinical Remission Data SELECT-MONOTHERAPY: Clinical Remission Data SELECT-MONOTHERAPY: Clinical Remission Data

SELECT‑MONOTHERAPY

Watch as Professor Paul Emery discusses RINVOQ efficacy and safety information from the SELECT‑MONOTHERAPY study.

SELECT-MONOTHERAPY Study Design

Video 1/4

Background information on a Phase 3 clinical trial program for RINVOQ as monotherapy.

SELECT-MONOTHERAPY Results

Video 2/4

A showcase of the results of the SELECT‑MONOTHERAPY study.

SELECT-MONOTHERAPY Safety Data

Video 3/4

A look at the safety data for the SELECT‑MONOTHERAPY study.

SELECT MONOTHERAPY Highlights

Video 4/4

Featuring the highlights of the SELECT‑MONOTHERAPY study and important safety information.

Switching from MTX to UPADAC monotherapy: See the results

 

Professor Paul Emery, Rheumatologist reviews SELECT-MONOTHERAPY, a phase 3 trial comparing MTX patients who switched to UPADAC vs those who remained on MTX.

Durable remission up to 1 year: RINVOQ + MTX vs placebo + MTX Durable remission up to 1 year: RINVOQ + MTX vs placebo + MTX Durable remission up to 1 year: RINVOQ + MTX vs placebo + MTX

SELECT‑COMPARE:
DAS28-CRP<2.6*
RINVOQ + MTX vs Placebo + MTX at Week 12

SELECT‑COMPARE:
DAS28-CRP<2.6*
RINVOQ + MTX vs Placebo + MTX at Week 12

SELECT-COMPARE: DAS28-CRP<2.6 RINVOQ + MTX vs Placebo + MTX at Week 12 SELECT-COMPARE: DAS28-CRP<2.6 RINVOQ + MTX vs Placebo + MTX at Week 12 SELECT-COMPARE: DAS28-CRP<2.6 RINVOQ + MTX vs Placebo + MTX at Week 12

*Does not mean drug-free remission or complete absence of disease activity

SELECT-COMPARE: Chart legend

Treatment groups are by initial randomization. Observations after rescue were handled using NRI (weeks 14-22) and LOCF (Week 26).2 For patients who discontinued at any time before or at Week 72, NRI was used.

P≤0.001 for RINVOQ + MTX vs Placebo + MTX; Analysis was not controlled for multiplicity;
P-value was obtained through nominal statistical testing.

Please see HUMIRA full Prescribing Information.

SELECT‑COMPARE was not designed to evaluate the efficacy of HUMIRA + MTX vs Placebo + MTX. No conclusions regarding this comparison can be made.

LTE limitations: There is potential for enrichment of LTE data; unblinding patients may cause bias related to overall treatment effect.

Please see HUMIRA full Prescribing Information.

Durable remission up to 1 year: RINVOQ vs MTX Durable remission up to 1 year: RINVOQ vs MTX Durable remission up to 1 year: RINVOQ vs MTX

SELECT‑MONOTHERAPY:
DAS28‑CRP<2.6*
RINVOQ vs MTX at Week 14

SELECT‑MONOTHERAPY:
DAS28‑CRP<2.6*
RINVOQ vs MTX at Week 14

SELECT-MONOTHERAPY: DAS28-CRP<2.6 RINVOQ vs MTX at Week 14 SELECT-MONOTHERAPY: DAS28-CRP<2.6 RINVOQ vs MTX at Week 14 SELECT-MONOTHERAPY: DAS28-CRP<2.6 RINVOQ vs MTX at Week 14

*Does not mean drug-free remission or complete absence of disease activity

Treatment groups are by initial randomization. Starting at Week 26, initiation of or change
in csDMARDs was allowed for patients who did not achieve CDAI≤10.3

Chart legend

RINVOQ SAFETY DATA

Review the well-studied safety profile of RINVOQ,
including both short- and long-term analyses

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking